Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among … – CDC

by | Dec 16, 2022 | COVID-19

Diya Surie, MD1,*; Jennifer DeCuir, MD, PhD1,*; Yuwei Zhu, MD2; Manjusha Gaglani, MBBS3,4; Adit A. Ginde, MD5; David J. Douin, MD5; H. Keipp Talbot, MD2; Jonathan D. Casey, MD2; Nicholas M. Mohr, MD6; Anne Zepeski, PharmD6; Tresa McNeal, MD3,4; Shekhar Ghamande, MD3,4; Kevin W. Gibbs, MD7; D. Clark Files, MD7; David N. Hager, MD, PhD8; Harith Ali, MBBS8; Leyla Taghizadeh9; Michelle N. Gong, MD10; Amira Mohamed, MD10; Nicholas J. Johnson, MD11; Jay S. Steingrub, MD12; Ithan D. Peltan, MD13; Samuel M. Brown, MD13; Emily T. Martin, PhD14; Akram Khan, MD15; William S. Bender, MD16; Abhijit Duggal, MD17; Jennifer G. Wilson, MD18; Nida Qadir, MD19; Steven Y. Chang, MD, PhD19; Christopher Mallow, MD20; Jennie H. Kwon, DO21; Matthew C. Exline, MD22; Adam S. Lauring, MD, PhD23; Nathan I. Shapiro, MD24; Cristie Columbus, MD4,25; Natasha Halasa, MD2; James D. Chappell, MD, PhD2; Carlos G. Grijalva, MD2; Todd W. Rice, MD2; William B. Stubblefield, MD2; Adrienne Baughman2; Kelsey N. Womack, PhD2; Jillian P. Rhoads, PhD2; Kimberly W. Hart, MA2; Sydney A. Swan, MPH2; Nathaniel M. Lewis, PhD1; Meredith L. McMorrow, MD1,†; Wesley H. Self, MD2,†; IVY Network (View author affiliations)
View suggested citationSummary
What is already known about this topic?
Immunity from monovalent COVID-19 mRNA vaccination wanes over time. A bivalent COVID-19 mRNA booster dose is recommended for all eligible persons; however, little is known about its effectiveness against COVID-19 hospitalization.
What is added by this report?
Among immunocompetent adults aged ≥65 years hospitalized in the multistate IVY Network, a bivalent booster dose provided 73% additional protection against COVID-19 hospitalization compared with past monovalent mRNA vaccination only.
What are the implications for public health practice?
To maximize protection against severe COVID-19 this winter season, all eligible persons, especially adults aged ≥65 years, should receive a bivalent booster dose and consider additional prevention strategies, including masking in indoor public spaces.



Article Attribution | Read More at Article Source

Share This